Bausch Health Companies (BHC) EBITDA (2009 - 2026)

Bausch Health Companies (BHC) has 18 years of EBITDA data on file, last reported at -$950.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 444.2% year-over-year to -$950.0 million; the trailing twelve-month figure through Mar 2026 stood at $587.0 million (down 61.91% YoY), and the FY2025 full-year result was $1.8 billion, up 17.27% from the prior year.
• EBITDA declined to -$950.0 million in Q1 2026, from $474.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $619.0 million in Q3 2025 to a low of -$950.0 million in Q1 2026.
• A 5-year average of $225.1 million and a median of $285.0 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA surged 2171.43% in 2024 and slumped 444.2% in 2026, its largest moves.
• Tracing BHC's EBITDA over 5 years: stood at -$236.0 million in 2022, then jumped by 253.39% to $362.0 million in 2023, then jumped by 54.14% to $558.0 million in 2024, then fell by 15.05% to $474.0 million in 2025, then sank by 300.42% to -$950.0 million in 2026.
• Business Quant data shows BHC's EBITDA at -$950.0 million in Q1 2026, $474.0 million in Q4 2025, and $619.0 million in Q3 2025.